keyword
MENU ▼
Read by QxMD icon Read
search

Enalapril

keyword
https://www.readbyqxmd.com/read/29776559/angioedema-in-heart-failure-patients-treated-with-sacubitril-valsartan-lcz696-or-enalapril-in-the-paradigm-hf-study
#1
Victor Shi, Michele Senni, Hendrik Streefkerk, Vikas Modgill, Wenchun Zhou, Allen Kaplan
BACKGROUND: PARADIGM-HF demonstrated significant clinical benefits for sacubitril/valsartan (LCZ696, an angiotensin receptor neprilysin inhibitor) versus the angiotensin-converting enzyme inhibitor (ACEI) enalapril in patients with heart failure with reduced ejection fraction. As inhibition of ACE, and co-inhibition of ACE and neprilysin, may increase the risk of angioedema, this was an adverse event of special interest. METHODS: Following sequential enalapril and sacubitril/valsartan run-ins, patients were randomized to twice-daily sacubitril/valsartan 200 mg or enalapril 10 mg...
August 1, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/29761293/stable-but-progressive-nature-of-heart-failure-considerations-for-primary-care-physicians
#2
REVIEW
Inder Anand
Primary care physicians play a significant role in managing heart failure (HF), with the goals of reducing mortality, avoiding hospitalization, and improving patients' quality of life. Most HF-related hospitalizations and deaths occur in patients with New York Heart Association functional class II or III, many of whom are perceived to have stable disease, which often progresses without clinical symptoms due to underlying deleterious effects of neurohormonal imbalance and endothelial dysfunction. Management includes lifestyle changes and stepped pharmacological therapy directed at the four stages of HF, with aggressive uptitration of therapies, including beta-blockers and inhibitors of the renin-angiotensin-aldosterone system...
May 14, 2018: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/29753906/continuous-inkjet-printing-of-enalapril-maleate-onto-orodispersible-film-formulations
#3
Yasmin Thabet, Dominique Lunter, Joerg Breitkreutz
Piezoelectric inkjet printing onto orodispersible films (ODFs) was proven to be a successful technique applying flexible doses of active pharmaceutical ingredients (APIs) onto edible substrates. The reported API printing and ODF production was conducted in a non-continuous production approach. Within this study, drug-free and hydrochlorothiazide (HCT) containing ODFs should be imprinted in-line with enalapril maleate (EM) ink during continuous ODF production. Macrogol inks based on various solvents and solvent-water mixtures were developed providing dynamic viscosities from 7 to 17 mPa∗s...
May 10, 2018: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/29748349/independent-prognostic-value-of-serum-soluble-st2-measurements-in-patients-with-heart-failure-and-a-reduced-ejection-fraction-in-the-paradigm-hf-trial-prospective-comparison-of-arni-with-acei-to-determine-impact-on-global-mortality-and-morbidity-in-heart-failure
#4
Eileen O'Meara, Margaret F Prescott, Brian Claggett, Jean L Rouleau, Lu-May Chiang, Scott D Solomon, Milton Packer, John J V McMurray, Michael R Zile
BACKGROUND: Soluble ST2 (sST2) is associated with cardiac remodeling and fibrosis. In chronic heart failure, the predictive value of sST2 has not been evaluated in a model that includes both NT-proBNP (N-terminal pro-B-type natriuretic peptide) and hs-TnT (high-sensitivity cardiac troponin T), in a trial in which treatment had a major impact. Therefore, the effects of treatment on sST2 levels in PARADIGM-HF trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure), the relationships between sST2 and outcomes, and the prognostic utility of various sST2 partition values were examined...
May 2018: Circulation. Heart Failure
https://www.readbyqxmd.com/read/29747834/platelet-count-affects-efficacy-of-folic-acid-in-preventing-first-stroke
#5
Xiangyi Kong, Xiao Huang, Min Zhao, Benjamin Xu, Richard Xu, Yun Song, Yaren Yu, Wenbin Yang, Jingping Zhang, Lishun Liu, Yan Zhang, Genfu Tang, Binyan Wang, Fan Fan Hou, Ping Li, Xiaoshu Cheng, Shuiping Zhao, Xiaobin Wang, Xianhui Qin, Jianping Li, Yong Huo
BACKGROUND: The role of platelets and important effect modifiers on the risk of first stroke is unknown. OBJECTIVES: This study examined whether low platelet count (PLT) and elevated total homocysteine (tHcy) levels jointly increase the risk of first stroke, and, if so, whether folic acid treatment is particularly effective in stroke prevention in such a setting. METHODS: A total of 10,789 Chinese hypertensive adults (mean age 59.5 years; 38% male, with no history of stroke and myocardial infarction) were analyzed from the China Stroke Primary Prevention Trial, where participants were randomly assigned to daily treatments of 10 mg enalapril and 0...
May 15, 2018: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/29723155/a-pilot-study-exploring-the-impact-of-cardiac-medications-on-ciliary-beat-frequency-possible-implications-for-clinical-management
#6
Rohit S Loomba, Abhinav Bhushan, Adeleye J Afolayan
BACKGROUND: Cilia are involved in several physiologic processes, and at least a single primary cilium can be found on nearly every cell in the human body. Various factors, such as pH, temperature, exposure to medications and toxins can impact ciliary function as is manifested by changes in the ciliary beat frequency. Those with ciliary dyskinesia may also have congenital cardiac malformations and may require care in a cardiac intensive care unit. This study investigates the effect on the ciliary beat frequency of medications frequently used in a cardiac intensive care unit...
May 3, 2018: Journal of Basic and Clinical Physiology and Pharmacology
https://www.readbyqxmd.com/read/29710617/illicit-drugs-and-pharmaceuticals-in-swimming-pool-waters
#7
G Fantuzzi, G Aggazzotti, E Righi, G Predieri, S Castiglioni, F Riva, E Zuccato
The occurrence of illicit drugs (cocaine, opioids, amphetamines and cannabis derivatives), some of their metabolites and 48 pharmaceuticals, was investigated in pool and source waters in ten Italian indoor swimming pools. The samples were analyzed by highperformance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS), after solid phase extraction (SPE). Cocaine and its metabolites were found in nine swimming pools, at concentrations from 0.3 to 4.2 ng/L for cocaine, 1.1 to 48.7 ng/L for norcocaine, 0...
April 20, 2018: Science of the Total Environment
https://www.readbyqxmd.com/read/29700011/an-investigation-of-drug-drug-interaction-alert-overrides-at-a-pediatric-hospital
#8
Kate Humphrey, Maria Jorina, Marvin Harper, Brenda Dodson, Seung-Yeon Kim, Al Ozonoff
OBJECTIVES: Drug-drug interactions (DDIs) can result in patient harm. DDI alerts are intended to help prevent harm; when the majority of alerts presented to providers are being overridden, their value is diminished. Our objective was to evaluate the overall rates of DDI alert overrides and how rates varied by specialty, clinician type, and patient complexity. METHODS: A retrospective study of DDI alert overrides that occurred during 2012 and 2013 within the inpatient setting described at the medication-, hospital-, provider-, and patient encounter-specific levels was performed at an urban, quaternary-care, pediatric hospital...
May 2018: Hospital Pediatrics
https://www.readbyqxmd.com/read/29687876/the-intervention-of-enalapril-maleate-and-folic-acid-tablet-on-the-expressions-of-the-grp78-and-chop-and-vascular-remodeling-in-the-vascular-smooth-muscle-cells-of-h-hypertensive-rats-with-homocysteine
#9
F Lu, L-Y Zhao, Z-M Zhang, Q Zou, X-L Yu, C-Y Wei
OBJECTIVE: GRP78 and CHOP play essential roles in endoplasmic reticulum stress (ERS) of the vascular smooth muscle cells. We aim to investigate the effect of enalapril maleate and folic acid tablet on the expressions of GRP78 and CHOP and vascular remodeling in a homocysteine (HCY)-treated hypertensive rat model. MATERIALS AND METHODS: The hypertensive rat model was established with the technique of coarctation in the abdominal aorta, and the blood pressure of the rat was measured with the non-destructive tail-cuff method two weeks after operation...
April 2018: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/29687191/sacubitril-valsartan-from-clinical-trials-to-real-world-experience
#10
REVIEW
Joanna M Joly, Akshay S Desai
PURPOSE OF REVIEW: Compared to enalapril, use of angiotensin-receptor blocker and neprilysin inhibitor sacubitril/valsartan to treat patients with heart failure and reduced ejection fraction (HFrEF) is associated with substantial reductions in both cardiovascular mortality and heart failure progression. The purpose of this review is to discuss the real-world experience of sacubitril/valsartan. RECENT FINDINGS: In the years following the publication of the landmark PARADIGM-HF trial in 2014 and its subsequent FDA approval, a growing evidence base supports the safety and efficacy of sacubitril/valsartan in a broad spectrum of patients with HFrEF...
April 23, 2018: Current Treatment Options in Cardiovascular Medicine
https://www.readbyqxmd.com/read/29661699/effect-of-neprilysin-inhibition-on-renal-function-in-patients-with-type-2-diabetes-and-chronic-heart-failure-who-are-receiving-target-doses-of-inhibitors-of-the-renin-angiotensin-system-a-secondary-analysis-of-the-paradigm-hf-trial
#11
Milton Packer, Brian Claggett, Martin P Lefkowitz, John J V McMurray, Jean L Rouleau, Scott D Solomon, Michael R Zile
BACKGROUND: Neprilysin inhibition has favourable effects on experimental diabetic nephropathy. We sought to assess the effects of neprilysin inhibition on the course of renal function in patients with type 2 diabetes. METHODS: In the randomised, double-blind PARADIGM-HF trial, the effects of sacubitril/valsartan (97 mg/103 mg twice daily) were compared with enalapril (10 mg twice daily) in 8399 patients with mild-to-moderate chronic heart failure and systolic dysfunction...
April 13, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29655829/renal-effects-and-associated-outcomes-during-angiotensin-neprilysin-inhibition-in-heart-failure
#12
Kevin Damman, Mauro Gori, Brian Claggett, Pardeep S Jhund, Michele Senni, Martin P Lefkowitz, Margaret F Prescott, Victor C Shi, Jean L Rouleau, Karl Swedberg, Michael R Zile, Milton Packer, Akshay S Desai, Scott D Solomon, John J V McMurray
OBJECTIVES: The purpose of this study was to evaluate the renal effects of sacubitril/valsartan in patients with heart failure and reduced ejection fraction. BACKGROUND: Renal function is frequently impaired in patients with heart failure with reduced ejection fraction and may deteriorate further after blockade of the renin-angiotensin system. METHODS: In the PARADIGM-HF (Prospective Comparison of ARNI with ACE inhibition to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial, 8,399 patients with heart failure with reduced ejection fraction were randomized to treatment with sacubitril/valsartan or enalapril...
April 5, 2018: JACC. Heart Failure
https://www.readbyqxmd.com/read/29653073/a-zebrafish-heart-failure-model-for-assessing-therapeutic-agents
#13
Xiao-Yu Zhu, Si-Qi Wu, Sheng-Ya Guo, Hua Yang, Bo Xia, Ping Li, Chun-Qi Li
Heart failure is a leading cause of death and the development of effective and safe therapeutic agents for heart failure has been proven challenging. In this study, taking advantage of larval zebrafish, we developed a zebrafish heart failure model for drug screening and efficacy assessment. Zebrafish at 2 dpf (days postfertilization) were treated with verapamil at a concentration of 200 μM for 30 min, which were determined as optimum conditions for model development. Tested drugs were administered into zebrafish either by direct soaking or circulation microinjection...
March 20, 2018: Zebrafish
https://www.readbyqxmd.com/read/29643067/incidence-predictors-and-outcomes-associated-with-hypotensive-episodes-among-heart-failure-patients-receiving-sacubitril-valsartan-or-enalapril-the-paradigm-hf-trial-prospective-comparison-of-angiotensin-receptor-neprilysin-inhibitor-with-angiotensin-converting
#14
Orly Vardeny, Brian Claggett, Jessica Kachadourian, Scott M Pearson, Akshay S Desai, Milton Packer, Jean Rouleau, Michael R Zile, Karl Swedberg, Martin Lefkowitz, Victor Shi, John J V McMurray, Scott D Solomon
BACKGROUND: In PARADIGM-HF (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure), heart failure treatment with sacubitril/valsartan reduced the primary composite outcome of cardiovascular death or heart failure hospitalization compared with enalapril but resulted in more symptomatic hypotension. Concern on hypotension may be limiting use of sacubitril/valsartan in appropriate patients...
April 2018: Circulation. Heart Failure
https://www.readbyqxmd.com/read/29626073/risk-of-incident-heart-failure-in-patients-with-diabetes-and-asymptomatic-left-ventricular-systolic-dysfunction
#15
Rasmus Rørth, Pardeep S Jhund, Ulrik M Mogensen, Søren L Kristensen, Mark C Petrie, Lars Køber, John J V McMurray
OBJECTIVE: Although diabetes is well known to be common in prevalent heart failure (HF) and portends a poor prognosis, the role of diabetes in the development of incident HF is less well understood. We studied the role of diabetes in the transition from asymptomatic left ventricular systolic dysfunction (ALVSD) to overt HF in the prevention arm of the Studies of Left Ventricular Dysfunction (SOLVD-P). RESEARCH DESIGN AND METHODS: We examined the development of symptomatic HF, HF hospitalization, and cardiovascular death according to diabetes status at baseline in patients in SOLVD-P...
April 6, 2018: Diabetes Care
https://www.readbyqxmd.com/read/29617523/effects-of-sacubitril-valsartan-on-physical-and-social-activity-limitations-in-patients-with-heart-failure-a-secondary-analysis-of-the-paradigm-hf-trial
#16
Alvin Chandra, Eldrin F Lewis, Brian L Claggett, Akshay S Desai, Milton Packer, Michael R Zile, Karl Swedberg, Jean L Rouleau, Victor C Shi, Martin P Lefkowitz, Tzvetana Katova, John J V McMurray, Scott D Solomon
Importance: Health-related quality of life (HRQL) of patients with heart failure is markedly reduced compared with that in patients with other chronic diseases, demonstrating substantial limitations in physical and social activities. In the Prospective Comparison of ARNI With an ACE-Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial, sacubitril/valsartan improved overall HRQL compared with enalapril, as determined by the Kansas City Cardiomyopathy Questionnaire (KCCQ)...
April 4, 2018: JAMA Cardiology
https://www.readbyqxmd.com/read/29601093/cost-effectiveness-analysis-of-sacubitril-valsartan-for-the-treatment-of-heart-failure-with-reduced-ejection-fraction-in-the-united-states
#17
Patrick M Zueger, Varun M Kumar, Rachel L Harrington, Gianna C Rigoni, Alicia Atwood, Robert J DiDomenico, Daniel R Touchette
OBJECTIVE: Sacubitril/valsartan (SAC/VAL) has been shown to reduce mortality and hospitalization in patients with heart failure with reduced ejection fraction (HFrEF) compared with enalapril but at a substantially higher cost. This study evaluates the cost-effectiveness of SAC/VAL versus enalapril in patients with HFrEF over a 5-year time horizon from the U.S. payer perspective. METHODS: A cohort-based Markov model was developed to compare costs and quality-adjusted life years (QALYs) between SAC/VAL and enalapril in patients with HFrEF over a 5-year time horizon...
March 30, 2018: Pharmacotherapy
https://www.readbyqxmd.com/read/29592815/treatment-optimization-of-angiotensin-converting-enzyme-inhibitors-and-associated-factors-in-ayder-comprehensive-specialized-hospital-a-cross-sectional-study
#18
Tesfay Mehari Atey, Tsegay Teklay, Solomon Weldegebreal Asgedom, Haftay Berhane Mezgebe, Gebrehiwot Teklay, Molla Kahssay
BACKGROUND: Angiotensin-converting enzyme inhibitors have morbidity and mortality benefits in heart failure. Failure to optimize treatment using these medications increases hospitalizations, worsens signs and symptoms of heart failure, and reduces the overall treatment outcome. Therefore, the main purpose of this study was to assess the practice of treatment optimization of these medications and associated factors. RESULTS: A hospital-based cross-sectional study was conducted on 61 ambulatory heart failure patients, recruited using a convenience sampling technique, from February 25 to May 24, 2016 at the cardiology clinic of Ayder Comprehensive Specialized Hospital...
March 28, 2018: BMC Research Notes
https://www.readbyqxmd.com/read/29580637/detection-of-renin-lineage-cell-transdifferentiation-to-podocytes-in-the-kidney-glomerulus-with-dual-lineage-tracing
#19
Diana G Eng, Natalya V Kaverina, Remington R S Schneider, Benjamin S Freedman, Kenneth W Gross, Jeffrey H Miner, Jeffrey W Pippin, Stuart J Shankland
Understanding of cellular transdifferentiation is limited by the technical inability to track multiple lineages in vivo. To overcome this we developed a new tool to simultaneously fate map two distinct cell types in the kidney, and genetically test whether cells of renin lineage (CoRL) can transdifferentiate to a podocyte fate. Ren1cCreER/tdTomato/Nphs1-FLPo/FRT-EGFP mice (CoRL-PODO mice) were generated by crossing Ren1c-CreER/tdTomato CoRL reporter mice with Nphs1-FLPo/FRT-EGFP podocyte reporter mice. Following tamoxifen administration in these animals, CoRL were labeled with red fluorescence (tdTomato) and co-localized with renin...
March 23, 2018: Kidney International
https://www.readbyqxmd.com/read/29567630/anthracycline-induced-cardiotoxicity-a-multicenter-randomised-trial-comparing-two-strategies-for-guiding-prevention-with-enalapril-the-international-cardiooncology-society-one-trial
#20
Daniela Cardinale, Fabio Ciceri, Roberto Latini, Maria Grazia Franzosi, Maria Teresa Sandri, Maurizio Civelli, GianFranco Cucchi, Elisabetta Menatti, Maurizio Mangiavacchi, Raffaele Cavina, Enrico Barbieri, Stefania Gori, Alessandro Colombo, Giuseppe Curigliano, Michela Salvatici, Antonio Rizzo, Francesco Ghisoni, Alessandra Bianchi, Cristina Falci, Michele Aquilina, Andrea Rocca, Anna Monopoli, Carlo Milandri, Giuseppe Rossetti, Marco Bregni, Marco Sicuro, Alessandra Malossi, Daniele Nassiacos, Claudio Verusio, Monica Giordano, Lidia Staszewsky, Simona Barlera, Enrico B Nicolis, Michela Magnoli, Serge Masson, Carlo M Cipolla
BACKGROUND: Troponin changes over time have been suggested to allow for an early diagnosis of cardiac injury ensuing cancer chemotherapy; cancer patients with troponin elevation may benefit of therapy with enalapril. It is unknown whether a preventive treatment with enalapril may further increase the benefit. METHODS: The International CardioOncology Society-one trial (ICOS-ONE) was a controlled, open-label trial conducted in 21 Italian hospitals. Patients were randomly assigned to two strategies: enalapril in all patients started before chemotherapy (CT; 'prevention' arm), and enalapril started only in patients with an increase in troponin during or after CT ('troponin-triggered' arm)...
May 2018: European Journal of Cancer
keyword
keyword
34397
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"